AstraZeneca (LSE:AZN) Q3 Results Fuel Profit Growth As Valuation Looms

AstraZeneca closed Friday at £139.60, capping a strong 90 day run, then dropped its Q3 2026 scorecard into an already optimistic tape. Traders initially focused on the headline beats, with total revenue at $16,209m and basic earnings per share at $2.01, and pushed the stock around the screens. Long term investors will likely look past that flicker and zero in on the real swing factor: a widening profit pool built on a 17.7% trailing net margin, which now sits against a rich P/E of 26.3x that markets will keep testing over the coming years.

Love AstraZeneca's 17.7% net margin but uneasy about paying a 26.3x P/E for a single pharma stock? Compare that trade-off with a wider field of high quality balance sheets using our list of solid balance sheet and fundamentals stocks (10 results)

Q3 2026 Earnings Summary

• Total Revenue, Q3 2026: US$16,209m vs. Q3 2025 US$15,191m (up about 6.7%)
• Net Income, Q3 2026: US$3,117m vs. Q3 2025 US$2,533m (up about 23.1%)
• Basic EPS, Q3 2026: US$2.01 vs. Q3 2025 US$1.63 (up about 23.1%)
• Net Profit Margin, Trailing 12 Months to Q3 2026: 17.7% vs. prior year 16.2% (higher margin profile)

Earnings grab the headlines, but valuation work usually starts with the cash flowing through AstraZeneca's business, not a single quarter's profit print. If you look at AstraZeneca's cash flows on their own, the stock could be a striking 42% undervalued.

AstraZeneca’s late stage engine starts to show through

Big picture, the bullish script says AstraZeneca can lean on a deeper, more focused late stage mix to carry it through patent cuts and heavier investment.

"The main requirement for this scenario is continued successful execution across the large Phase III portfolio, including tozorakimab, elecoglipron, efzimfotase alfa, and other opportunities valued at more than US$5 billion, so that these programs offset loss of exclusivity and higher capital expenditure."

Q3 and year to date data point in that direction. Total revenue rose 7% while core EPS advanced 14%, even with Farxiga and wider CVRM pressure. Oncology revenue increased 16% to US$21.9b and rare disease climbed 11% to US$7.5b, supported by 12 positive Phase III readouts and multiple new approvals. That mix shift helps validate the late stage growth premise, at least for now.

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.

AstraZeneca’s missed shots keep pipeline risk alive

Bearish investors worry AstraZeneca’s late stage engine looks powerful on slides yet leaks value when individual assets encounter real world trial risk.

"Although AstraZeneca highlights broad late stage oncology and biologics assets, the failed primary endpoint in the SERENA-4 trial for Etcamah limits expansion in first line ER positive, HER2 negative breast cancer and could leave earnings more exposed to patent expiries if other high value biologics and ADC programs also underdeliver on expected revenue and margins."

The latest quarter confirms that concern has teeth. SERENA-4 and Wainua setbacks sit alongside strong oncology and rare disease data, so aggregate revenue and EPS still advance. Yet replacement breadth now relies more heavily on winners such as Enhertu, Imfinzi and tozorakimab, which increases concentration risk if any of those future readouts disappoint.

Hunt For Mispriced Cash Engines

AstraZeneca’s latest quarter shows how quickly sentiment can shift around a single earnings report. The real opportunity lies in identifying stocks that appear undervalued before the market reevaluates them.

• Company 1 - 43% below our estimate - uses a rebuilt cloud platform and AI assisted coding to roll out new savings tools faster for members and partners.
• Company 2 - 34% below our estimate - leans on a growing membership base and recommerce logistics to reuse returned appliances instead of treating them as pure delivery cost.
• Company 3 - 22% below our estimate - scales long cycle defense programs, munitions and autonomous systems so expanding backlogs translate into higher production volumes and service work.

Three companies from the same screener. Open all 13 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com